Rhoda Alani, MD
Professor
Boston University School of Medicine
Dept of Dermatology

MD, University of Michigan at Ann Arbor



Rhoda M. Alani, MD is the Herbert Mescon Professor and Chair of Dermatology at Boston University School of Medicine and Boston Medical Center. She received her MD degree with Honors and Distinction in Research from the University of Michigan and completed her internship in internal medicine at Yale-New Haven Hospital and a residency in dermatology at Harvard Medical School. From 1999-2009 Dr. Alani was the Director of the Laboratory of Cutaneous Oncology and Director of the Melanoma and Pigmented Lesion Clinics in Dermatology at Johns Hopkins. Dr. Alani’s research focus is in understanding the molecular basis of melanoma development and progression with the aim of translating her laboratory findings to better prevention, detection, diagnosis, and treatment of melanoma. Dr. Alani is a member of Phi Beta Kappa and Alpha Omega Alpha Honor Societies, the American Academy of Dermatology, the Society for Investigative Dermatology, the American Association for Cancer Research and was elected to the American Society for Clinical Investigation in 2005. She is the author of numerous scientific publications and is the owner of several US patents related to melanoma biomarkers, novel melanoma therapies, and imaging systems for improved melanoma detection

Herbert Mescon Chair of Dermatology
Boston University School of Medicine
Dermatology


Professor
Boston University School of Medicine
Pathology & Laboratory Medicine


Mentor for Graduate Medical Students
Boston University School of Medicine, Division of Graduate Medical Sciences



2010 MD Anderson Cancer Center: Inaugural Graduate Student Professor of the Year Lecturer
2009 Johns Hopkins University School of Medicine: Stewart Scholar Award in Cancer Research
2008 Johns Hopkins University School of Medicine: Dermatology Residents Leadership and Teaching Recognition Award
2006 Harvard Medical School: Outstanding Alumna
2003 American Skin Association: Scholar Award for Melanoma Research
2001 Stewart Scholar Award in Cancer Research


Center for Innovation in Point of Care Technologies for the Future of Cancer Care
07/01/2012 - 06/30/2017 (SP Co-PI of Sub-Project / SP)
PI: Catherine M. Klapperich, PhD
NIH/National Institute of Biomedical Imaging & Bioengineering
5U54EB015403-04

PESO: Engineered Platforms to Investigate Molecular Determinants of Tumor Metastasis to Targeted Niche Sites
09/01/2012 - 08/31/2016 (Co-PI)
National Science Foundation
DMR-1235316

Melanoma Assays Based on NRP-2
05/01/2010 - 09/30/2015 (PI)
Laboratory Corporation of America


Modeling the Metastasis of Malignant Melanoma Using Microfluidic Platforms
01/01/2014 - 12/31/2014 (PI)
American Skin Association


Evaluating Melanoma Using Engineered Metastatic Platforms: A Potential for High Throughout Screening and Drug Discovery
04/01/2013 - 03/31/2014 (PI)
Joanna M. Nicolay Melanoma Foundation





Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Eisenstein A, Gonzalez EC, Raghunathan R, Xu X, Wu M, McLean EO, McGee J, Ryu B, Alani RM. Emerging Biomarkers in Cutaneous Melanoma. Mol Diagn Ther. 2018 04; 22(2):203-218.View Related Profiles. PMID: 29411301.
     
  2. Eisenstein A, Panova IP, Chung HJ, Goldberg LJ, Zhang Q, Lazova R, Bhawan J, Busam KJ, Symanowski JT, Alani RM, Ryu B. Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions. Melanoma Res. 2018 Feb; 28(1):71-75.View Related Profiles. PMID: 29227334.
     
  3. Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA. Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nat Commun. 2018 01 04; 9(1):53.View Related Profiles. PMID: 29302039.
     
  4. Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017 Mar; 4(1):13-37.View Related Profiles. PMID: 28758010.
     
  5. Hsu MY, Yang MH, Schnegg CI, Hwang S, Ryu B, Alani RM. Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis. Lab Invest. 2017 Jun; 97(6):725-736.View Related Profiles. PMID: 28165469; DOI: 10.1038/labinvest.2017.1;.
     
  6. Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 2016 Aug; 26(4):321-8.View Related Profiles. PMID: 26881875; DOI: 10.1097/CMR.0000000000000190;.
     
  7. Alani RM, Larson A, Falanga V. Paving a New Path Towards Academic Medicine-A Novel Approach to Graduate Medical Education in the United States. Acad Med. 2016 08; 91(8):1039-40.View Related Profiles. PMID: 27465087; DOI: 10.1097/ACM.0000000000001269;.
     
  8. Zhang C, Barrios MP, Alani RM, Cabodi M, Wong JY. A microfluidic Transwell to study chemotaxis. Exp Cell Res. 2016 Mar 15; 342(2):159-65. PMID: 26988422; DOI: 10.1016/j.yexcr.2016.03.010;.
     
  9. Zhang C, Shenk EM, Blaha LC, Ryu B, Alani RM, Cabodi M, Wong JY. A simple engineered platform reveals different modes of tumor-microenvironmental cell interaction. Biofabrication. 2016 Mar; 8(1):015001. PMID: 26716792; PMCID: PMC4854650; DOI: 10.1088/1758-5090/8/1/015001;.
     
  10. Alani RM, Cole PA, Yan G, Bowers EM. USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES. 2015.
     
Showing 10 of 89 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 89 publications over 28 distinct years, with a maximum of 10 publications in 2009

YearPublications
19841
19872
19891
19912
19921
19932
19961
19973
19983
19991
20013
20021
20033
20044
20053
20062
20078
20085
200910
20104
20116
20125
20134
20144
20152
20163
20172
20183
Contact for Mentoring:


609 Albany St (J Bldg)
Boston MA 02118
Google Map


Alani's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department